Contralateral subfrontal approach for tuberculum sellae meningioma: techniques and clinical outcomes

Yeong Jin Kim, MD, PhD, Kyung-Sub Moon, MD, PhD, Woo-Youl Jang, MD, Tae-Young Jung, MD, PhD, In-Young Kim, MD, PhD, and Shin Jung, MD, PhD

Department of Neurosurgery, Chonnam National University Research Institute of Medical Science, Chonnam National University Hwasun Hospital & Medical School, Hwasun, Jeollanam-do, South Korea

OBJECTIVE Tuberculum sellae meningiomas (TSMs) present a burdensome surgical challenge because of their adjacency to vital neurovascular structures. The contralateral subfrontal approach provides an outstanding corridor for removing a TSM with an excellent visual outcome and limited complications. The authors present their long-term surgical experience in treating TSMs via the contralateral subfrontal approach and discuss patient selection, surgical techniques, and clinical outcomes.

METHODS Between 2005 and 2021, the authors used the contralateral subfrontal approach in 74 consecutive patients presenting with TSMs. The surgical decision-making process and surgical techniques are described, and the clinical outcomes were retrospectively analyzed.

RESULTS The mean patient age was 54.4 years, with a female predominance (n = 61, 82%). Preoperatively, 61 patients (82%) had vision symptoms and 73 (99%) had optic canal invasion by tumor. Gross-total resection was achieved in almost all patients (n = 70, 95%). The visual function improvement and stabilization rate was 91% (67/74). Eight patients (11%) showed a worsening of visual function on the less-compromised (approach-side) optic nerve. There was no occurrence of cerebrospinal fluid leakage. Four patients (5%) experienced recurrences after the initial operation (mean follow-up duration 63 months). There were no deaths in this study.

CONCLUSIONS The contralateral subfrontal approach provides a high chance of complete tumor removal and visual improvement with limited complications and recurrences, especially when the tumor is in a unilateral or midline location causing unilateral visual symptoms or bilateral asymmetrical visual symptoms, regardless of tumor size or encasement of major vessels. With the appropriate patient selection, surgical technique, and familiarity with surrounding neurovascular structures, this approach is reliable for TSM surgery.

https://thejns.org/doi/abs/10.3171/2022.5.JNS212899

KEYWORDS tuberculum sellae meningioma; contralateral subfrontal; visual outcome; tumor relapse; oncology

T UBERCULUM sellae meningiomas (TSMs) are challenging tumors given their proximity to the optic nerve, internal carotid artery (ICA), anterior cerebral artery (ACA), and infundibulum. Almost all TSMs invade the optic canal and displace the optic nerve superiorly and laterally, causing visual impairment.¹ Consequently, complete tumor removal and the preservation of visual function without complications are the important goals of TSM treatment.

Various surgical approaches are currently used for the treatment of TSMs. Both transcranial and transsphenoidal approaches have remarkably advanced over the decades to accomplish their surgical goals. Each type of surgical ap-

proach provides certain superiority or inferiority, and the optimal surgical approach remains controversial.

Although the contralateral subfrontal approach has been used for the resection of TSMs, previous reports have included only a small number of patients or short-term follow-up data.² The purpose of this study was to analyze the long-term surgical outcomes of patients with TSMs treated via the contralateral subfrontal approach and to present surgical tips for this approach.

Methods

This study was approved by the institutional review

ABBREVIATIONS ACA = anterior cerebral artery; CSF = cerebrospinal fluid; EMF = electromagnetic field; ICA = internal carotid artery; ICH = intracranial hematoma; GTR = gross-total resection; MRI = magnetic resonance imaging; OCI = optic canal invasion; RT = radiotherapy; STR = subtotal resection; TSM = tuberculum sellae meningioma; VIS = visual impairment score; WHO = World Health Organization.

SUBMITTED December 20, 2021. ACCEPTED May 20, 2022.

INCLUDE WHEN CITING Published online July 22, 2022; DOI: 10.3171/2022.5.JNS212899.

board of the Chonnam National University Hwasun Hospital. The clinical records and imaging data of patients who had undergone the contralateral subfrontal approach for TSM at our institution between 2005 and 2021 were retrospectively reviewed. Medical records and pre- and postoperative magnetic resonance imaging (MRI) data were also reviewed. Patients with planum sphenoidale meningioma and clinoidal meningioma were excluded from this study. Seventy-four consecutive newly diagnosed patients matched the inclusion criteria. Although a wait-andsee approach was possible in asymptomatic patients, given the characteristics of TSM, we supposed that early proactive surgery could achieve better surgical outcomes in patients with relatively small tumors and no visual symptoms. And the close proximity of TSMs to the optic nerve excluded radiosurgery as the first treatment option. Some patient data on visual outcomes have been used in our previous study.²

Preoperative MR images with a standard 1.5- and 3.0-T MRI system and preoperative CT images with 1.2-mmthick slices were obtained in all patients. Multiplanar reconstruction imaging enabled identification of the relationship between tumor and surrounding anatomical structures such as the optic canal, optic nerve, infundibulum, ICA, and ACA. The size of the tumor was measured as the maximal tumor diameter based on axial T1-weighted images with contrast. "Major vessel involvement" was regarded as a contact area of the tumor around the ICA and ACA of more than 270°. Optic canal invasion (OCI) was evaluated with postcontrast MR and CT images. The distance between optic canals was measured on the basis of CT images at the tuberculum sellae level. Follow-up MRI scans were acquired 6 and 18 months after surgery and biennially thereafter. Gross-total resection (GTR) was defined as Simpson grade I or II removal in the surgical record and was confirmed by an independent radiologist on enhancing MR images within 6 months after surgery. Tumors that did not remain radiologically visible but were reported as residual tumors during surgery were considered as cases of subtotal resection (STR). Tumor relapse was defined as a recurrence in GTR cases or as tumor growth in cases of incomplete resection.

The visual impairment score (VIS) was used to quantify the patient's visual status in the pre- and postoperative periods. The VIS, created by the German Ophthalmological Society, is a practical scoring system reflecting visual field, visual acuity, and balance of both eyes.³ Visual acuity was tested with best-correcting glasses (Snellen notations), and visual field defects were evaluated using Goldmann perimetry. The postoperative visual outcomes were graded as improved, stable, or deteriorated, according to the changes. For statistical analysis, the improved or stable group was classified as a "favorable" outcome and the deteriorated group was classified as an "unfavorable" outcome.

Surgical Technique

The contralateral subfrontal approach was performed via a unilateral subfrontal approach. The patient was placed supine with the head fixed in a Sugita head holder. The head was rotated 20° - 30° toward the side of the tu-

mor with mild extension to allow the frontal lobe to fall away from the anterior cranial fossa. Excessive head rotation of more than 30° resulted in less surgical space and interfered with the surgical procedure. A frontotemporal curvilinear skin incision was made, and a frontotemporal craniotomy was performed. The sphenoid wing was flattened with a drilling procedure until the meningo-orbital band was exposed. The dura mater was incised in a curvilinear fashion over the inferior frontal and anterior temporal areas. The sylvian fissure was dissected to provide cerebrospinal fluid (CSF) drainage for relaxation of the brain. The use of lumbar drainage for brain relaxation was unnecessary. A self-retaining retractor was not needed to retract the brain. The olfactory nerve was dissected from the frontal lobe for preservation. After identifying the approach-side optic nerve and ICA, the tumor capsule was opened, followed by internal debulking. Dural attachment of the tumor was coagulated and dissected to devascularize the tumor. Internal debulking facilitated separation of the tumor-arachnoid plane, which detached the tumor from the approach-side optic nerve spontaneously without manipulation of the optic nerve. Reduction of the tumor in a piecemeal fashion was continued until the affectedside optic nerve, optic chiasm, and pituitary stalk were identified. The posterior part of the tumor was removed, preserving the pituitary stalk. Then, sharp dissection was performed along the tumor-arachnoid plane with a direct view of the inferomedial aspect of the optic nerve. A direct view of the inferomedial aspect of the lesion-side optic nerve enabled dissection between the tumor and the affected-side optic nerve without manipulation of the optic nerve. The falciform ligament, the medial roof of the optic canal, was cut to release tension on the optic nerve and unroof the optic canal. Tumor invading the optic canal was easily removed by widening the optic canal using an electromagnetic field (EMF) system. There was no need to drill out the bony structures surrounding the optic nerve to remove tumor invading the optic canal. After tumor removal, the origin site of the tumor was coagulated using bipolar cautery or an EMF system.

Statistical Analysis

Statistical analyses were conducted using the Statistical Package for the Social Sciences (SPSS) version 27 (IBM Corp.) and R software (R Foundation for Statistical Computing). The patient and tumor characteristics and postoperative outcomes, including visual outcomes, tumor relapse, and complications, were analyzed using descriptive statistics. The means of numeric variables and the distribution of categorical variables between groups were compared using the Wilcoxon rank-sum test and Fisher's exact test, respectively. Firth's logistic regression model was used to adjust for possible confounding in the analysis of visual outcomes, tumor relapse, and complications. Probability values < 0.05 were considered statistically significant.

Results

Characteristics of the Patients and Tumors

The 74 patients included in the study consisted of 13

J Neurosurg Volume 138 • March 2023 599

males and 61 females. The mean patient age at the time of surgery was 54.4 years (range 25-83 years), and the median follow-up duration was 63 months (range 2-185 months). The main presenting symptoms included visual impairment (61 patients, 82%), headache (5 patients, 7%), and dizziness (1 patient, 1%). Seven patients (9%) were asymptomatic. The mean maximum tumor diameter was 21.1 mm (range 8–43 mm). Major vessel encasement was evident in 20 patients (27%), and OCI was identified in 73 patients (99%). The mean distance between optic canals was 15.2 mm (range 11-19 mm). Most patients (68 patients, 92%) had a histologically confirmed World Health Organization (WHO) grade I meningioma, whereas only 6 patients (8%) had confirmed WHO grade II meningioma. The pathological diagnoses included meningothelial (70%), transitional (7%), fibrous (5%), psammomatous (4%), syncytial (3%), angiomatous (3%), chordoid (4%), and atypical (4%) types. Clinical and radiological characteristics are summarized in Table 1.

Visual Outcomes

Sixty-one patients (82%) had preoperative visual impairment related to TSMs, and the median symptom duration was 4 months (range 1-120 months). Thirty-three patients (45%) had unilateral visual impairment, and 28 (38%) had bilateral visual impairment. The mean preoperative VIS was 23.2 ± 22.53 (range 0–100). Of the 61 patients with preoperative visual impairment, 41 (67%) had improved visual function, 13 (21%) had stable visual function, and 7 (11%) experienced deterioration after surgery. All patients without preoperative visual impairment had visual function that remained stable. The less-compromised-side or approach-side visual function was deteriorated in 8 patients (11%). The mean postoperative VIS was 15.1 ± 18.45 (range 0–100). The results of an analysis of variables that could be correlated with the preservation of visual function are shown in Table 2. Variables such as preoperative visual symptoms, tumor size, signal intensity on T2-weighted MRI, and extent of resection did not reach statistical significance in visual outcomes. A WHO grade I (p = 0.009) and the absence of adjuvant radiotherapy (RT; p = 0.042) resulted in favorable visual outcomes on univariate analysis. The absence of adhesion to the optic nerve (OR 7.81, 95% CI 1.13–152.27, p = 0.036) and a leftside subfrontal approach (OR 66.57, 95% CI 2.47-1.01e⁺⁴, p = 0.006) were related to favorable visual outcomes as independent prognostic factors.

Complications

Surgery-related complications were observed in 10 patients (14%). Two patients experienced early-onset seizures and were in a seizure-free state without antiepileptic drugs at the last follow-up. Two patients had decreased olfactory function. Three patients developed postoperative intracranial hematoma (ICH) accompanying ischemic stroke, and 2 of the 3 underwent surgical intervention. Only 1 of the patients with postoperative ICH had sequelae (hand-grasp difficulty) at the last follow-up. There were no other stroke events or restricted diffusion on the MR images. Two patients had endocrinological disorders, one of whom had

TABLE 1. Clinical characteristics and surgical outcomes in
74 patients with TSMs treated via the contralateral subfrontal
approach

Variable	Value
Mean age in yrs (range)	54.4 (25-83)
Female gender (%)	61 (82)
Mean MRI FU duration in mos (range)	63 (2–185)
No. of patients w/ preop visual disturbance (%)	61 (82)
Mean duration of symptoms in mos (range)	4 (1–120)
Mean max tumor diameter in mm (range)	21.2 (8–43)
No. of major vessel encasements (%)	20 (27)
No. of OCIs (%)	73 (99)
No. of lateralized tumors (%)	40 (54)
No. of diaphragm sella invasions (%)	31 (42)
No. w/ high SI on T2-weighted images (%)	50 (68)
Mean distance btwn optic canals in mm (range)	15.2 (11–19)
Mean op time in mins (range)	292 (125-470)
Histological WHO grade, no. (%)	
<u> </u>	68 (92)
<u> </u>	6 (8)
	0
Extent of resection, no. (%)	
GTR	70 (95)
STR	4 (5)
Adjuvant RT, no. (%)	4 (5)
Visual outcome, no. (%)	
Improved	41 (55)
Stable	26 (35)
Deteriorated	7 (9)
Recurrence, no. (%)	4 (5)
Complication, no. (%)	10 (14)

FU = follow-up; SI = signal intensity.

hypopituitarism after postoperative meningitis. However, none of the patients experienced transient or permanent diabetes insipidus. Hydrocephalus was observed in 1 patient and improved after lumbar drainage. There were no instances of CSF leakage in our series. On univariate analysis, symptom duration, tumor size, and proximity to surrounding structures were statistically significantly related to the occurrence of complications. However, on further multivariate logistic regression analysis, no factor showed statistical significance (Table 3).

Tumor Control

GTR was achieved and confirmed during surgery and by postoperative MRI in 70 patients (95%). Four patients (5%) underwent STR. The specific cause of STR included tight adhesion to the surrounding structure, such as the lesion-side optic nerve (n = 2, each remnant was < 8% of the total volume) or pituitary stalk (n = 1, the remnant was < 1% of the total volume) and invasion of the cavernous sinus (n = 1, remnant was 19% of the total volume). There were no statistically significant factors affecting the ex-

TABLE 2. Factors predictive of favorable visual outcomes

Factor Favorable Unfavorable Analysis p Value OR 95% CI Age in yrs 56 (47–61) 57 (47–58) 0.448 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 0.814 <		Visual	Outcome	Univariato		Multivar	iate Analysis
Age in yrs 56 (47–61) 57 (47–58) 0.448 Gender	Factor	Favorable	Unfavorable	Analysis	p Value	OR	95% CI
Gender Male 12 1 Male 12 1 0.814 Female 55 6 0.814 Visual disturbance Yes 54 7 No 13 0 0.095 Duration of symptoms in mos 3 (2-9) 13 (3-43) 0.244 Tumor diameter in mm 20 (15-25) 23 (20-30) 0.18 Major vessel encasements	Age in yrs	56 (47–61)	57 (47–58)	0.448			
Male 12 1 0.814 Female 55 6 0.914 Visual disturbance $Visual disturbance$ 0.095 0.095 No 13 0 0.095 0.244 Tumor diameter in mm 20 (15-25) 23 (20-30) 0.244 0.095 Major vessel encasements 0.006 0.072 5.89 $0.86-68.64$ OCIs 0.006 0.072 5.89 $0.86-68.64$ OCIs 0.048 0.072 5.89 $0.86-68.64$ OCIs 0.049 0.049 0.649 0.012 Laterality of tumor 54 5 0.649 0.649 Diatinvasion 54 5 0.649 0.649 Lateralized tumor 30 4 0.649 0.649 Diaphragm sella invasion 12 2 0.649 0.649 Distarce btwn optic canals in mm 15 (14-16) 15 (15-18) 0.307 0.009 0.079 63	Gender						
Female 55 6 0.814 Visual disturbance Visual disturbance 0.095 0.095 No 13 0 0.095 0.095 Duration of symptoms in mos 3 (2-9) 13 (3-43) 0.244 0.095 Major vessel encasements 0.08 0.072 5.89 0.86-68.64 Ves 16 4 0.08 0.072 5.89 0.86-68.64 OCIs None 1 0 0.649 0.649 0.649 Bilat invasion 12 2 0.649 0.408 0.72 5.89 0.86-68.64 Ves 16 4 0.649 0.649 0.649 0.649 0.649 0.649 0.649 0.649 0.649 0.649 0.649 0.649 0.649 0.649 0.649 0.649 0.649 0.649 0.649 0.649 0.649 0.675 0.64 0.675 0.64 0.675 0.64 0.675 0.64 0.675 0.665 0.665	Male	12	1				
Visual disturbance Ves 54 7 0.095 No 13 0 0.095 0.095 0.095 Tumor diameter in mm 20 (15-25) 23 (20-30) 0.18 0.072 5.89 0.86-68.64 Major vessel encasements 0.08 0.072 5.89 0.86-68.64 0.015 None 1 0 0.016 0.012 0.012 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011	Female	55	6	0.814			
Yes 54 7 0.095 No 13 0 0.095 Duration of symptoms in mos 3 (2-9) 13 (3-43) 0.244 Tumor diameter in mm 20 (15-25) 23 (20-30) 0.18 Major vessel encasements 0.08 0.072 5.89 0.86-68.64 None 1 0 0.04 0.649 0.649 Unilat invasion 54 5 0.649 0.649 0.649 Laterality of tumor 30 4 0.408 0.649 0.649 Laterality of tumor 37 3 0.408 0.408 0.649 Laterality of tumor 37 3 0.408 0.408 0.675 Usiphragm sella invasion 12 2 0.122 1 0.675 1 Isointense or low 21 3 0.675 1 1 Isointense or low 21 3 0.675 1 1 I 64 6 0.307 1 <t< td=""><td>Visual disturbance</td><td></td><td></td><td></td><td></td><td></td><td></td></t<>	Visual disturbance						
No 13 0 0.095 Duration of symptoms in mos 3 (2-9) 13 (3-43) 0.244 Tumor diameter in mm 20 (15-25) 23 (20-30) 0.18 Major vessel encasements No 51 3 0.08 0.072 5.89 0.86-68.64 Ves 16 4 0.08 0.072 5.89 0.86-68.64 OCIs None 1 0 0.649 0.649 0.408 Bilat invasion 12 2 0.408 0.408 0.408 Lateralized tumor 30 4 0.408 0.408 0.408 Vess 26 5 0.122 1.10 1.10 Yes 26 5 0.122 1.10 1.10 Vess 26 5 0.122 1.10 1.10 Isointense or low 21 3 0.675 0.41 0.70-3.23e+07 Itistological WHO grade I 64 6 0.334 0.70-3.23e+07	Yes	54	7				
$\begin{array}{c c c c c c c } \hline Duration of symptoms in mos & 3 (2-9) & 13 (3-43) & 0.244 \\ \hline Tumor diameter in mm & 20 (15-25) & 23 (20-30) & 0.18 \\ \hline Major vessel encasements & & & & & & & & & & & & & & & & & & &$	No	13	0	0.095			
Tumor diameter in mm 20 (15–25) 23 (20–30) 0.18 Major vessel encasements	Duration of symptoms in mos	3 (2–9)	13 (3-43)	0.244			
Major vessel encasements No 51 3 0.08 0.072 5.89 0.86–68.64 OCIs None 1 0 0.08 0.072 5.89 0.86–68.64 OCIs None 1 0 0 0.649 0.649 Unitat invasion 54 5 0.649 0.408 0.408 Lateralized tumor 30 4 0.408 0.408 0.408 Diaphragm sella invasion 37 3 0.408 0.408 0.408 No 41 2 0.408 0.408 0.408 0.408 Disphragm sella invasion 51 3 0.475 0.42 0.408 Isointense or low 21 3 0.675 0.46 0.307 High 46 4 0.009 0.079 63.61 0.70–3.23e+07 Extend of resection GTR 64 6 0.334 0.465 1.36e-04 to 1.32e+03 Yes 2 2 0.042	Tumor diameter in mm	20 (15–25)	23 (20–30)	0.18			
No 51 3 0.08 0.072 5.89 0.86–68.64 Yes 16 4 0 0 0.072 5.89 0.86–68.64 OCIs	Major vessel encasements		,				
Yes1640.08 0.072 5.89 $0.86-68.64$ OCIsNone10Unilat invasion545Bilat invasion122Laterality of fumor304Midline tumor304Lateralized tumor373Diaphragm sella invasion0.408No412Yes265T2 SI 0.122 Isointense or low213Distance brw noptic canals in mm15 (14-16)J 16 644 0.675 High464O.122 0.079 63.61 $0.70-3.23e+07$ I33CTR646STR3 0.009 O.07963.61 $0.70-3.23e+07$ I33Adjuvant RT 0.042 0.923 No655Yes22No655Yes205Adhesion 0.036 7.81No472Yes205Approach side $11.32e-03$ Lt290Di 0.338 O.006 66.57 $2.47-1.01e+04$	No	51	3				
OCts None 1 0 Unilat invasion 54 5 0.649 Bilat invasion 12 2 Laterality of tumor 30 4 Midline tumor 30 4 Lateralized tumor 37 3 0.408 Diaphragm sella invasion 0 0.122 1 No 41 2 0.122 Yes 26 5 0.122 Yes 21 3 0.675 Distance btwn optic canals in mm 15 (14–16) 15 (15–18) 0.307 Histological WHO grade I 64 6 0.334 Adjuvant RT No 65 5 0.042 0.923 0.65 1.36e-04 to 1.32e+03	Yes	16	4	0.08	0.072	5.89	0.86-68.64
None 1 0 Unilat invasion 54 5 0.649 Bilat invasion 12 2 Lateralized tumor 30 4 0.408 Diaphragm sella invasion 37 3 0.408 Diaphragm sella invasion 0.122 \sim \sim No 41 2 0.122 Yes 26 5 \sim Isointense or low 21 3 \circ High 46 4 \circ \circ Isointense or low 21 3 \circ \circ High 46 4 \circ \circ \circ Isointense or low 21 3 \circ \circ \circ Isointense or low 21 3 \circ \circ \circ Isointense or low 21 \circ \circ \circ \circ Isointense or low 21 \circ \circ \circ \circ Istological WHO grade	OCIs						
Unilat invasion 54 5 0.649 Bilat invasion 12 2 Laterality of tumor 30 4 0.408 Lateralized tumor 37 3 0.408 Diaphragm sella invasion 0.122 0.122 No 41 2 0.122 Yes 26 5 0.122 Isointense or low 21 3 0.675 T2 SI 0.675 0.122 Isointense or low 21 3 0.675 High 46 4 0.009 0.079 63.61 0.70–3.23e+07 I 64 4 0.334 0.334 0.334 0.334 0.70–3.23e+07 Extent of resection GTR 64 6 0.334 0.70–3.23e+07 Keyse 2 2 0.042 0.923 0.65 1.36e-04 to 1.32e+03 Yes 2 2 0.042 0.923 0.65 1.36e-04 to 1.32e+03 Yes 2	None	1	0				
Bilat invasion 12 2 Laterality of tumor 30 4 0.408 Lateralized tumor 37 3 0.408 Diaphragm sella invasion 0.408 0.408 No 41 2 0.122 Yes 26 5 0.122 T2 SI 0.675 0.675 High 46 4 0.675 High 46 4 0.009 0.079 63.61 0.70–3.23e+07 Histological WHO grade 1 3 3 0.65 1.66e-04 to 1.32e+03 STR 3 1 0.334 0.334 0.334 0.65 1.36e-04 to 1.32e+03 Yes 2 2 0.042 0.923 0.65 1.36e-04 to 1.32e+03 Yes 2 2 0.04 0.036 7.81 1.13–152.27 Yes 20 5 0.04 0.036 7.81 1.13–152.27 Yes 20 5 0.038 0.006	Unilat invasion	54	5	0.649			
Laterality of tumor 30 4 0.408 Midline tumor 37 3 0.408 Lateralized tumor 37 3 0.408 Diaphragm sella invasion 0.122 0.122 Yes 26 5 0.122 Yes 26 5 0.122 Isointense or low 21 3 0.675 High 46 4 0.675 Distance btwn optic canals in mm 15 (14–16) 15 (15–18) 0.307 Histological WHO grade 1 64 4 0.009 0.079 63.61 0.70–3.23e+07 I 64 6 0.334 0.009 0.079 63.61 0.70–3.23e+07 I 64 6 0.334 0.009 0.079 63.61 0.70–3.23e+07 Extent of resection	Bilat invasion	12	2	-			
Midline tumor 30 4 0.408 Lateralized tumor 37 3 0.408 Diaphragm sella invasion No 41 2 0.122 Yes 26 5 0.122 T2 SI Isointense or low 21 3 0.675 High 46 4 0.675 0.122 Isointense or low 21 3 0.675 Distance btwn optic canals in mm $15(14-16)$ $15(15-18)$ 0.307 Histological WHO grade 1 64 4 0.009 0.079 63.61 $0.70-3.23e+07$ I 64 6 0.334 0.009 0.079 63.61 $0.70-3.23e+07$ It 3 3 0.009 0.079 63.61 $0.70-3.23e+07$ It 3 1 0.334 0.923 0.65 $1.36e-04$ to $1.32e+03$ Yes 2 2 0.04 0.036 7.81 1.13	Laterality of tumor						
Interval Image: constraint of the section of the sectio	Midline tumor	30	4				
Diaphragm sella invasion O 41 2 No 41 2 0.122 Yes 26 5 0.122 T2 SI Isointense or low 21 3 0.675 High 46 4 0.675 Distance btwn optic canals in mm 15 (14–16) 15 (15–18) 0.307 Histological WHO grade I 64 4 0.009 0.079 63.61 0.70–3.23e+07 II 64 6 0.334 0.334 0.334 0.334 0.334 Adjuvant RT No 65 5 0.042 0.923 0.65 1.36e-04 to 1.32e+03 Yes 2 2 0.042 0.923 0.65 1.36e-04 to 1.32e+03 Preop VIS 14 (7–35) 17 (4–30) 0.743 0.65 1.36e-04 to 1.32e+03 Adhesion Ves 20 5 0.04 0.036 7.81 1.13–152.27 Approach side It 29 0 0.038 0.006 </td <td>l ateralized tumor</td> <td>37</td> <td>3</td> <td>0.408</td> <td></td> <td></td> <td></td>	l ateralized tumor	37	3	0.408			
No 41 2 0.122 Yes 26 5 0.122 Isointense or low 21 3 0.675 High 46 4 0.675 Distance btwn optic canals in mm 15 (14–16) 15 (15–18) 0.307 Histological WHO grade 1 64 4 0.009 0.079 63.61 $0.70-3.23e+07$ II 64 6 0.334 0.334 0.334 $0.70-3.23e+07$ Extent of resection GTR 64 6 0.334 $0.70-3.23e+07$ Katheward RT 0.334 0.334 0.334 $0.70-3.23e+07$ No 65 5 0.042 0.923 0.65 $1.36e-04$ to $1.32e+03$ Yes 2 2 0.042 0.923 0.65 $1.36e-04$ to $1.32e+03$ Preop VIS 14 (7-35) 17 (4-30) 0.743 $1.13-152.27$ Adhesion Ves 20 5 0.038 0.006 66.57	Diaphragm sella invasion						
Yes 26 5 0.122 T2 SI Isointense or low 21 3 0.675 High 46 4 0.675 Distance btwn optic canals in mm 15 (14–16) 15 (15–18) 0.307 Histological WHO grade 64 4 0.009 0.079 63.61 0.70–3.23e+07 I 64 6 0.334 0.334 0.334 0.012 0.923 0.65 1.36e-04 to 1.32e+03 GTR 64 6 0.334 0.923 0.65 1.36e-04 to 1.32e+03 Adjuvant RT No 65 5 0.042 0.923 0.65 1.36e-04 to 1.32e+03 Yes 2 2 0.04 0.036 7.81 1.13–152.27 Yes 20 5 0.04 0.036 7.81 1.13–152.27 Yes 20 5 0.04 0.036 7.81 1.13–152.27 Yes 20 5 0.038 0.006 66.57 2.47–1.01e+04 <	No	41	2				
T2 SI Isointense or low 21 3 0.675 High 46 4 0.675 Distance btwn optic canals in mm 15 (14–16) 15 (15–18) 0.307 Histological WHO grade 1 64 4 I 64 4 0.009 0.079 63.61 0.70–3.23e+07 II 3 3 0.009 0.079 63.61 0.70–3.23e+07 Extent of resection	Yes	26	5	0.122			
Isointense or low 21 3 0.675 High 46 4 0.675 Distance btwn optic canals in mm 15 (14–16) 15 (15–18) 0.307 Histological WHO grade 1 64 4 0.009 0.079 63.61 0.70–3.23e+07 I 64 6 0.334 0.334 0.334 0.334 Extent of resection 0.334 0.334 0.092 0.65 1.36e-04 to 1.32e+03 Yes 2 2 0.042 0.923 0.65 1.36e-04 to 1.32e+03 Preop VIS 14 (7–35) 17 (4–30) 0.743 1.13–152.27 Adhesion 20 5 0.04 0.036 7.81 1.13–152.27 Yes 20 5 0.038 0.006 66.57 2.47–1.01e+04	T2 SI		•				
High 46 4 0.675 Distance btwn optic canals in mm 15 (14–16) 15 (15–18) 0.307 Histological WHO grade I 64 4 0.009 0.079 63.61 0.70–3.23e+07 I 64 4 0.009 0.079 63.61 0.70–3.23e+07 I 3 3 0.009 0.079 63.61 0.70–3.23e+07 Extent of resection 3 1 0.334 Adjuvant RT 3 1 0.334 0.923 0.65 1.36e-04 to 1.32e+03 Yes 2 2 0.042 0.923 0.65 1.36e-04 to 1.32e+03 Preop VIS 14 (7–35) 17 (4–30) 0.743 Adhesion 0.04 0.036 7.81 1.13–152.27 Approach side 0.038 0.006 66.57 2.47–1.01e+04	Isointense or low	21	3				
$\begin{array}{c c c c c c c c } \hline \text{Distance btwn optic canals in mm} & 15 (14-16) & 15 (15-18) & 0.307 \\ \hline \text{Histological WHO grade} & & & & \\ \hline I & 64 & 4 & & & \\ \hline I & 3 & 3 & & & & \\ \hline I & 3 & 3 & & & & \\ \hline I & 3 & 3 & & & & \\ \hline \text{Extent of resection} & & & & & \\ \hline \text{Extent of resection} & & & & & \\ \hline \text{GTR} & 64 & 6 & & & \\ \hline \text{GTR} & 64 & 6 & & & \\ \hline \text{STR} & 3 & 1 & & & \\ \hline \text{Adjuvant RT} & & & & & \\ \hline \text{No} & 65 & 5 & & & \\ \hline \text{Ves} & 2 & 2 & & & \\ \hline \text{Preop VIS} & 14 (7-35) & 17 (4-30) & 0.743 & & \\ \hline \text{Adhesion} & & & & \\ \hline \text{No} & & 47 & 2 & & \\ \hline \text{No} & & 47 & 2 & & \\ \hline \text{No} & & 47 & 2 & & \\ \hline \text{Yes} & & 20 & 5 & & \\ \hline \text{No} & & & & & \\ \hline \text{No} & & & & & \\ \hline \text{No} & & & & & & \\ \hline \text{No} & & & & & & \\ \hline \text{No} & & & & & & \\ \hline \text{No} & & & & & & \\ \hline \text{No} & & & & & & & \\ \hline \text{No} & & & & & & & \\ \hline \text{No} & & & & & & & \\ \hline \text{No} & & & & & & & \\ \hline \text{No} & & & & & & & \\ \hline \text{No} & & & & & & & \\ \hline \text{No} & & & & & & & \\ \hline \text{No} & & & & & & & \\ \hline \text{No} & & & & & & & \\ \hline \text{No} & & & & & & & \\ \hline \text{No} & & & & & & & \\ \hline \text{No} & & & & & & & \\ \hline \text{No} & & & & & & & \\ \hline \text{No} & & & & & & & \\ \hline \text{No} & & & & & & & \\ \hline \text{No} & & & & & & & \\ \hline \text{No} & & & & & & & \\ \hline \text{No} & & & & & & & \\ \hline \text{No} & & & & & & & \\ \hline \text{No} & & & & & & & \\ \hline \text{No} & & & & & & & \\ \hline \text{No} & & & & & & & \\ \hline \text{No} & & & & & & & \\ \hline \text{No} & & & & & & & \\ \hline \text{No} & & & & & & & \\ \hline \text{No} & & & & & & & \\ \hline \text{No} & & & & & & & \\ \hline \text{No} & & & & & & & \\ \hline \text{No} & & & & & & & \\ \hline \text{No} & & & & & & & \\ \hline \text{No} & & & & & & & \\ \hline \text{No} & & & & & & & \\ \hline \text{No} & & & & & & & \\ \hline \text{No} & & & & & & & \\ \hline \text{No} & & & & & & \\ \hline \text{No} & & & & & & \\ \hline \text{No} & & & & & & \\ \hline \text{No} & & & & & & \\ \hline \text{No} & & & & & & \\ \hline \text{No} & & & & & & \\ \hline \text{No} & & & & & & \\ \hline \text{No} & & & & & & \\ \hline \text{No} & & & & & & \\ \hline \text{No} & & & & & & \\ \hline \text{No} & & & & & & \\ \hline \text{No} & & & & & & \\ \hline \text{No} & \text{No} & & & & \\ \hline \text{No} & \text{No} & & & & \\ \hline \text{No} & \text{No} & & & & \\ \hline \text{No} & \text{No} & & & & \\ \hline \text{No} & \text{No} & & & & \\ \hline \text{No} & \text{No} & & & & \\ \hline \text{No} & \text{No} & & & \\ \hline \text{No} & \text{No} & & & \\ \hline N$	High	46	4	0.675			
Histological WHO grade I 64 4 0.009 0.079 63.61 $0.70-3.23e+07$ II 3 3 0.009 0.079 63.61 $0.70-3.23e+07$ Extent of resection 0.334 0.334 0.334 0.334 0.334 Adjuvant RT 3 1 0.334 0.042 0.923 0.65 $1.36e-04$ to $1.32e+03$ Yes 2 2 0.042 0.923 0.65 $1.36e-04$ to $1.32e+03$ Preop VIS 14 (7-35) 17 (4-30) 0.743 $1.13-152.27$ No 47 2 0.04 0.036 7.81 $1.13-152.27$ Approach side 11 29 0 0.038 0.006 66.57 $2.47-1.01e+04$	Distance btwn optic canals in mm	15 (14–16)	15 (15–18)	0.307			
I 64 4 0.009 0.079 63.61 0.70–3.23e+07 II 3 3 0.009 0.079 63.61 0.70–3.23e+07 Extent of resection 64 6 0.334 0.334 0.334 GTR 64 6 0.334 0.334 0.334 0.334 Adjuvant RT 0.00 65 5 0.042 0.923 0.65 1.36e-04 to 1.32e+03 Yes 2 2 0.042 0.923 0.65 1.36e-04 to 1.32e+03 Preop VIS 14 (7–35) 17 (4–30) 0.743 0.046 7.81 1.13–152.27 Adhesion Ves 20 5 0.04 0.036 7.81 1.13–152.27 Approach side It 29 0 0.038 0.006 66.57 2.47–1.01e+04	Histological WHO grade	- (- /	- (/				
II 3 3 0.009 0.079 63.61 0.70–3.23e+07 Extent of resection 3 3 0.009 0.079 63.61 0.70–3.23e+07 GTR 64 6 0.334 0.334 0.334 0.334 Adjuvant RT 3 1 0.042 0.923 0.65 1.36e-04 to 1.32e+03 Yes 2 2 0.042 0.923 0.65 1.36e-04 to 1.32e+03 Preop VIS 14 (7–35) 17 (4–30) 0.743 0.036 7.81 1.13–152.27 Adhesion 47 2 0.04 0.036 7.81 1.13–152.27 Approach side 1 1.13–152.27 0.038 0.006 66.57 2.47–1.01e+04		64	4				
Extent of resection GTR 64 6 0.334 GTR 3 1 0.334 Adjuvant RT 3 1 0.334 Adjuvant RT 65 5 0.042 0.923 0.65 1.36e-04 to 1.32e+03 Yes 2 2 0.042 0.923 0.65 1.36e-04 to 1.32e+03 Preop VIS 14 (7–35) 17 (4–30) 0.743 0.743 Adhesion 47 2 0.04 0.036 7.81 1.13–152.27 Yes 20 5 0.04 0.036 7.81 1.13–152.27 Approach side 11 29 0 0.038 0.006 66.57 2.47–1.01e+04		3	3	0.009	0.079	63.61	0.70-3.23e+07
GTR 64 6 0.334 STR 3 1 0.334 Adjuvant RT 0.042 0.923 0.65 1.36e-04 to 1.32e+03 Yes 2 2 0.042 0.923 0.65 1.36e-04 to 1.32e+03 Preop VIS 14 (7–35) 17 (4–30) 0.743 0.043 0.036 7.81 1.13–152.27 No 47 2 0.04 0.036 7.81 1.13–152.27 Yes 20 5 0.04 0.036 7.81 1.13–152.27 Approach side 29 0 0.038 0.006 66.57 2.47–1.01e+04	Extent of resection						
STR 3 1 0.334 Adjuvant RT 0.334 No 65 5 Yes 2 2 Preop VIS 14 (7–35) 17 (4–30) Adhesion 0.042 0.923 No 47 2 Yes 20 5 Approach side 0.044 0.036 Lt 29 0 Pt 28 7	GTR	64	6				
Adjuvant RT No 65 5 0.042 0.923 0.65 1.36e-04 to 1.32e+03 Yes 2 2 0.042 0.923 0.65 1.36e-04 to 1.32e+03 Preop VIS 14 (7–35) 17 (4–30) 0.743 0.743 Adhesion 47 2 0.04 0.036 7.81 1.13–152.27 Yes 20 5 0.04 0.036 7.81 1.13–152.27 Approach side U 29 0 0.038 0.006 66.57 2.47–1.01e+04	STR	3	1	0.334			
No 65 5 0.042 0.923 0.65 $1.36e-04$ to $1.32e+03$ Yes 2 2 0.042 0.923 0.65 $1.36e-04$ to $1.32e+03$ Preop VIS 14 (7–35) 17 (4–30) 0.743 Adhesion 17 2 0.04 0.036 7.81 No 47 2 0.04 0.036 7.81 Yes 20 5 0.04 0.036 7.81 Approach side $1112-152.27$ $1112-152.27$ Pt 29 0 0.038 0.006 Bt 29 7 0.038 0.006 66.57	Adjuvant RT		-				
No 47 2 Yes 20 5 Preop VIS 14 (7–35) 17 (4–30) O.42 0.923 0.65 1.36e-04 to 1.32e+03 Adhesion 0.743 No 47 2 Yes 20 5 Approach side Lt 29 0 Pt 28 7 0.038 0.006 66.57 2.47–1.01e+04	No	65	5				
No 47 2 Yes 20 5 Approach side Lt 29 0 Pt 28 7 0.036 7.81 1.13-152.27	Yes	2	2	0.042	0.923	0.65	1.36e-04 to 1.32e+03
Adhesion Adhesion No 47 2 Yes 20 5 Approach side 1.13–152.27 Lt 29 0 Dt 28 7 0.038 0.006 66.57 2.47–1.01e+04	Preop VIS	14 (7-35)	17 (4-30)	0.743			
No 47 2 0.04 0.036 7.81 1.13–152.27 Yes 20 5 0.04 0.036 7.81 1.13–152.27 Approach side	Adhesion			0.110			
Yes 20 5 0.04 0.036 7.81 1.13–152.27 Approach side Lt 29 0 0.038 0.006 66.57 2.47–1.01e+04	No	47	2				
Approach side 29 0 0.038 0.006 66.57 2.47–1.01e+04	Yes	20	5	0.04	0.036	7.81	1.13–152.27
Lt 29 0 Dt 28 7 0.038 0.006 66.57 2.47-1.01e+04	Approach side		•				
D+ 28 7 0.038 0.006 66.57 2.47-1.01e+04	†	29	0				
DU 30 (Rt	38	7	0.038	0.006	66.57	2.47-1.01e+04

The median and interquartile range of the numeric variables and the number of categorical variables are represented. Boldface type indicates statistical significance.

tent of resection, including tumor size, OCI, and artery encasement. There was no remnant near the approach-side optic nerve. One patient with a residual tumor had atypical meningioma and received adjuvant RT. Another had fibrous meningioma and underwent adjuvant stereotactic radiosurgery. All residual tumors remained stable at the last follow-up. Recurrence after GTR was observed in 4 (5%) patients 38, 55, 78, and 119 months after surgery

J Neurosurg Volume 138 • March 2023 601

TABLE 3. Factors predictive of complications

	Comp	olication	Univariate	Mu	Itivariate /	Analysis
Factor	No	Yes	Analysis	p Value	OR	95% CI
Age in yrs	56 (48–61)	57 (42–69)	0.943			
Gender		i				
Male	53	8	0.024			
Female	11	2	0.831			
Visual disturbance						
Vision	52	9	0 707			
Other	12	1	0.737			
Duration of symptoms in mos	3 (1–8)	15.5 (5–63)	0.005	0.31	1.02	0.98–1.05
Tumor diameter in mm	19.5 (15–25)	29 (23–35)	0.003	0.709	1.03	0.88–1.19
Major vessel encasements						
No	51	3	0.000	0.070	0.00	0 5 44 90
Yes	13	7	0.003	0.273	2.33	0.5-11.60
OCIs						
None	1	0				
Unilat invasion	53	6	0.214			
Bilat invasion	10	4				
Laterality of tumor						
Midline tumor	28	6	0.244			
Lateralized tumor	36	4	0.344			
Diaphragm sella invasion						
No	41	2	0.014	0.021	1.00	014 016
Yes	23	8	0.014	0.931	1.09	0.14-8.16
T2 SI						
Isointense or low	22	2	0.494			
High	42	8	0.404			
Distance btwn optic canals in mm	15 (14–16)	15 (14–16.75)	0.753			
Histological WHO grade						
1	60	8	0.194			
II	4	2	0.104			
Extent of resection						
GTR	61	9	0.449			
STR	3	1	0.440			
Adjuvant RT						
No	62	8	0.086	0.57	2.81	0.1 16/ 08
Yes	2	2	0.000	0.57	2.01	0.1-104.90
Preop VIS	14 (7–33)	30 (6–77)	0.226			
Adhesion						
No	43	6	0 725			
Yes	21	4	0.725			
Approach side						
Lt	25	4	0.056			
Rt	39	6	0.300			

The median and interquartile range of numeric variables and the number of categorical variables are represented. Boldface type indicates statistical significance.

(Fig. 1). The recurrence sites included the inferomedial side of the approach-side optic nerve with tumor invading the approach-side optic canal (n = 2) and the inferolateral side of the lesion-side optic nerve with tumor encasing the

ICA (n = 2). One patient had chordoid meningioma and received adjuvant RT but experienced recurrence. The tumor size (mean 28.5 mm, range 22-43 mm) in recurrence cases was relatively larger than that in the other cases, but



FIG. 1. Kaplan-Meier estimates of relapse-free survival after the contralateral subfrontal approach for the treatment of TSM. Figure is available in color online only.

there was no statistically significant difference between the two groups. Other preoperative anatomical factors, such as optic canal involvement and vessel encasement, did not affect tumor recurrence.

Surgical Outcomes Associated With Tumor Scoring

We divided our TSM series into 14 subtypes, according to the tumor-canal-artery subtype classifications (Supplemental Fig. 1).⁴ Tumor control and visual outcomes were not significantly affected by scale scores. The incidence of complications was affected by artery scores (p = 0.029) and total scores (p = 0.009) in the univariate analysis. Patients with a scale score of 4 or higher tended to have poor tumor control and visual outcomes (not significant) as well as complications (p = 0.014).

Discussion

Although previous studies on surgical approaches for TSM have reported favorable results, the optimal surgical approach for TSM remains controversial (Tables 4 and 5). Various surgical approaches are available for the management of TSM, including the transcranial approach and the transsphenoidal approach. Considering the anatomical specialty in TSM, the optimal surgical approach for TSM should be modulated according to patient and tumor characteristics. Because of the specific location of TSMs, complete tumor removal, lower complication rates, and favorable visual outcomes are the major concerns in adopting the optimal surgical approach. The key to preserving visual function is to minimize the manipulation of optic nerves and avoid injury to the blood supply to the optic nerves. Exact preoperative assessments for selecting the proper surgical approach and fine intraoperative techniques have made it possible to achieve the surgical goals. The contralateral subfrontal approach could be an excellent choice for removing a TSM when the tumor is in a unilateral or midline location causing unilateral visual symptoms or bilateral asymmetrical visual symptoms. The contralateral subfrontal approach provides a direct view of the tumor and OCI with less manipulation of the optic nerve and reduces the possibility of CSF leakage, regardless of tumor size, extent, or vascular encasement. Tumor scoring is a detailed objective parameter and gives more persuasive criteria for selecting surgical approaches and anticipating outcomes. In our series, patients with a tumor score of 3 or lower tended to have excellent surgical outcomes (Supplemental Fig. 1). Even in high-score tumors, the contralateral subfrontal approach demonstrated surgical outcomes comparable to those obtained with other transcranial approaches and transsphenoidal approaches.⁴

Total tumor removal without recurrence is the one of the most important goals in TSM treatment. In recent series, the GTR rate was 53%–96% with other transcranial approaches and 50%-95% with transsphenoidal approaches (Tables 4 and 5). In our study, the GTR rate was 95% (70/74). Through the contralateral subfrontal approach, the inferomedial portion of the affected optic nerve and tumor invading the optic canal are clearly exposed. Opening the optic canal via the contralateral subfrontal approach is easy because the tumor compresses the optic nerve from the inferomedial side of the optic nerve. A small volume of tumor invasion into the optic canal causes severe compression of the optic nerve because of the intrinsically restricted space of the optic canal. A direct view of the optic canal and simple removal of the falciform ligament enable removal of the tumor without bone drilling (Fig. 2). The optic canal is not the center of the tumor, and an OCI tumor could be easily removed without damage to the compromised optic nerve.5

Blind spots in the surgical field may result in STR because of blind resection and unexpected manipulation of the neurovascular structures. During the contralateral subfrontal approach, the inferomedial side of the approachside optic nerve and the inferolateral side of the affectedside optic nerve are less exposed, and the removal of tumor in this site is a little more difficult than tumors in other locations. There are specific considerations in overcom-

TABLE 4. Literature re	view of tra	anscranial sei	ries and clinical	outcomes								
-	No. of	Visual	Improved After	Unchanged After	Worsened After	GTR	Complication	Recurrence	CSF	Hypopituitarism	No. of	Mean FU
Authors & Year	Patients	Assessment	Surgery (%)	Surgery (%)	Surgery (%)	(%)	(%)	(%)	Leakage (%)	(%)	Deaths (%)	(sou)
Wang et al., 2011 ²¹	45	45	27 (60)	12 (27)	6 (13)	40 (89)	16 (36)	3 (7)	2 (4)	2 (4)	1 (2)	39
Chokyu et al., 2011 ²²	34	32	28 (87)	4 (13)	0	27 (79)	2 (6)	NA	0	0	0	96
Li-Hua et al., 2011 ²³	67	67	43 (64)	20 (30)	4 (6)	62 (93)	19 (28)	NA	1 (1)	4 (6)	0	29
Curey et al., 2012 ²⁴	20	20	14 (70)	4 (20)	2 (10)	19 (95)	10 (50)	0	0	1 (5)	0	56
Palani et al., 2012 ²⁵	41	41	11 (27)	27 (66)	3 (7)	30 (73)	5 (12)	NA	2 (5)	1 (2)	2 (5)	NA
Romani et al., 2012 ²⁶	52	52	22 (42)	22 (42)	8 (16)	45 (87)	17 (33)	1 (2)	3 (6)	5 (10)	1 (2)	59
Mortini et al., 2012 ²⁷	36	36	31 (86)	4 (11)	1 (3)	32 (89)	9 (25)	4 (11)	1 (3)	5 (14)	0	30
Margalit et al., 2013 ²⁸	51	43	20 (46)	21 (49)	2 (5)	45 (88)	10 (20)	0	3 (6)	0	1 (2)	42
Seol et al., 2013 ²⁹	86	73	32 (44)	27 (37)	14 (19)	74 (86)	35 (40)	5 (6)	NA	2 (2)	NA	39
Mariniello et al., 2013 ³⁰	44	44	27 (61)	11 (25)	6 (14)	38 (86)	NA	2 (4)	NA	NA	NA	120
Liu et al., 2015 ³¹	21	21	13 (62)	7 (33)	1 (5)	NA	5 (24)	NA	5 (24)	NA	0	15
Lee et al., 2016 ¹⁰	100	100	70 (70)	25 (25)	5 (5)	96 (96)	12 (12)	2 (2)	0	0	0	58
Zhou et al., 2016 ³²	56	56	47 (84)	7 (12)	2 (4)	50 (89)	23 (41)	NA	2 (4)	12 (21)	0	27
Karsy et al., 2017 ³³	49	46	17 (37)	28 (61)	1 (2)	42 (86)	16 (36)	NA	2 (4)	4 (8)	0	42
Song et al., 2018 ⁹	40	38	15 (39)	14 (37)	9 (24)	26 (65)	18 (45)	13 (33)	0	6 (15)	1 (3)	44
Kong et al., 2018 ³⁴	94	77	43 (56)	21 (27)	13 (17)	75 (80)	6 (8)	NA	0	0	1 (1)	28
Xu et al., 2019 ³⁵	23	22	12 (55)	8 (36)	2 (9)	23 (100)	8 (35)	0	0	3 (13)	0	40
Cai et al., 2019 ¹⁵	30	29	17 (59)	8 (28)	4 (13)	27 (90)	5 (17)	1 (3)	0	1 (3)	0	NA
NA = not available.												

Kim et al.

IABLE 5. Literature review	of transsp	nenoidal seri	les and clinica	l outcomes								
			Improved	Unchanged	Worsened				CSF		No. of	
	No. of	Visual	After	After	After	GTR	Complication	Recurrence	Leakage	Hypopituitarism	Deaths	Mean FU
Authors & Year	Patients	Assessment	Surgery (%)	Surgery (%)	Surgery (%)	(%)	(%)	(%)	(%)	(%)	(%)	(som)
Van Gompel et al., 2011 ³⁶	13	12	8 (67)	4 (34)	0	7 (54)	1 (8)	NA	0	0	0	21
Ogawa & Tominaga, 201237	19	19	14 (73)	3 (16)	2 (11)	15 (79)	1 (5)	1 (5)	1 (5)	0	0	36
Khan et al., 2014 ³⁸	17	14	9 (64)	5 (36)	0	11 (65)	5 (29)	NA	2 (12)	3 (18)	0	10
Ceylan et al., 2015 ³⁹	23	20	14 (70)	6 (30)	0	17 (74)	4 (17)	NA	2 (9)	2 (9)	0	NA
Hayashi et al., 2017 ⁴⁰	22	18	15 (83)	3 (17)	0	15 (68)	3 (14)	NA	0	2 (9)	0	NA
Bander et al., 2018 ⁴¹	17	16	10 (63)	6 (37)	0	14 (82)	13 (76)	2 (12)	2 (12)	0	0	25
Song et al., 2018 ⁹	44	44	43 (98)	0	1 (2)	37 (84)	24 (55)	6 (14)	1 (2)	3 (7)	0	27
Elshazly et al., 2018 ⁴²	25	22	15 (68)	7 (32)	0	19 (76)	7 (28)	1 (4)	2 (8)	3 (12)	0	21
Kong et al., 2018 ³⁴	84	80	68 (85)	8 (10)	4 (5)	70 (83)	10 (12)	NA	4 (5)	0	1 (1)	28
Youngerman et al., 202143	51	46	31 (67)	12 (26)	3 (7)	40 (78)	14 (27)	9 (18)	5 (10)	2 (4)	0	40
Yu et al., 2021 ⁴⁴	40	40	38 (95)	2 (5)	0	38 (95)	12 (30)	1 (3)	3 (8)	0	0	15

ing blind resection and unexpected manipulations. First, appropriate patient selection is important. A lateralized tumor or midline tumor with lateralized visual symptoms suggests that the tumor is located in a unilateral optic nerve without adhesion to the less-compromised optic nerve. These tumor characteristics reduce the requirement for blind resection. Second, the head rotation angle should be between 20° and 30° to maximize the surgical corridor between the optic nerves, and the approach-side optic nerve should be vertical to the operating room floor. Third, flattening of the sphenoid wing and anterior cranial fossa with the proper head extension makes sufficient space between the skull base and the frontal lobe with less brain retraction. These measures to maximize the surgical corridor are also related to good visual outcomes.

The recurrence rate is closely related to the postoperative follow-up duration.⁶ In a recent series, the recurrence rate was 0%-33% in other transcranial approaches and 3%-18% in transsphenoidal approaches with quite different follow-up durations (Tables 4 and 5). Only a few studies using transcranial approaches have reported recurrence rates from more than 5 years' follow-up duration. There have been no studies on the transsphenoidal approach with more than 5 years of follow-up. The shortest interval between surgery and relapse was 38 months in the present series. Considering these results, the recurrence rate in this study is more convincing than in other studies in which the follow-up duration was shorter than in our series. We speculate that a high GTR rate and the use of an EMF system to remove involved dura mater through a clear, wide surgical view were related to the low recurrence rate in the long-term follow-up.

The contralateral subfrontal approach for TSM provides a clear view of OCI and the inferomedial side of the optic nerve without optic nerve manipulation and results in comparable visual outcomes with acceptable visual function on the approach-side optic nerve. The preservation of or improvement in visual function is an important goal for TSM treatment. In using other transcranial or transsphenoidal approaches, the visual deterioration rates were 0%-30% and 0%–11%, respectively, in recent large series (Tables 4 and 5). In our study, the preservation or improvement rate of visual function was 91% and the deterioration rate was 9%. These results were also demonstrated in previous reports on the contralateral approach for TSM (Table 6). Minimal optic nerve manipulation and the absolute preservation of vessels supplying the optic pathway are crucial for postoperative visual outcomes. The vascularization of the optic pathway in the cisternal segment is intricate, considering the ACA, ophthalmic artery, and superior hypophyseal artery. These arteries enter the arachnoid membrane of the optic nerve, which could be tightly adhered to the tumor capsule.^{7,8} The contralateral subfrontal approach makes it comfortable to dissect the tumor-arachnoid plane and preserve fragile vascular structures. The OCI is also a cardinal concern in completely removing TSM without visual impairment. Optic canal decompression is an essential procedure to remove tumors in the optic canal. The contralateral subfrontal approach can provide sufficient space for safe unroofing of the involved optic canal. Various factors, such as age, preoperative visual symptoms,



FIG. 2. The ipsilateral (A–C) and contralateral (D–F) subfrontal approaches in the 3D reconstruction model based on MRI and the intraoperative view. The 3D reconstruction model (**A and B**) shows the ipsilateral subfrontal approach. The approach for a tumor (*green*) located in the inferomedial aspect of the compromised optic nerve (*yellow*) is blocked by the optic nerve. *Red* indicates arteries (ICA, ACA, and middle cerebral artery). The intraoperative view (**C**) demonstrates the blind spot and hidden tumor (*white arrows*, B and C) in the inferomedial aspect of the optic nerve. The 3D reconstruction model (**D and E**) shows the contralateral subfrontal approach. The inferomedial aspect of the optic nerve is clearly exposed. The intraoperative view (**F**) demonstrates the clear view of the inferomedial aspect of the optic nerve. The *white arrowheads* (E and F) indicate the well-exposed inferomedial aspect of the optic nerve; Rt. = right. Figure is available in color online only.

tumor size, tight adhesion to the optic nerve, and extent of resection, have been suggested as prognostic factors for postoperative visual outcomes in patients with TSM.9-12 In our study, tight adhesion to the optic nerve and the surgical approach side were significant prognostic factors for postoperative visual outcomes in patients with TSM. Among right-handed surgeons, the operator usually holds and swaps the bipolar forceps, tumor forceps, microscissors, dissector, or pincette in the right hand. In contrast to the left hand, which continuously holds the suction device, the frequent swapping of surgical instruments and the relatively larger-sized instruments compared to the suction device cause insensate manipulation of the optic nerve. This tendency may be more prominent when the right optic nerve is located in the foremost surgical field and close to the surgeon's right hand, interfering with right-hand motion. Although adhesion is an unchangeable characteristic of the tumor, poor outcomes related to a right-sided subfrontal approach are correctable. In addition to the surgical technique for GTR described above, the operator keeps in mind that the surgical instruments should move parallelly to the approach-side optic nerve and the optic nerve should be vertical to the operating room floor to maintain a sufficient surgical field. It is postulated that, in the case of a tumor severely adhered to the optic nerve with an inconvenient working corridor, accidental manipulation of the optic nerve or injury to the vascular structure may occur with high probability and cause poor visual outcomes. To prevent undesirable, unexpected injury to the optic nerve, the surgical tips mentioned above should be kept in mind.

In recent series, the nonvisual complication rate was 6%-50% in other transcranial approaches and 5%-76% in transsphenoidal approaches (Tables 4 and 5). A relatively low incidence of complications and the absence of CSF leakage were observed in the present study. In particular, there was no chance of CSF leakage in the contralateral subfrontal approach given the intact barrier between the brain and paranasal sinus. Since optic canal unroofing is accompanied only by removal of the falciform ligament, there is no chance to open the paranasal sinus in the contralateral subfrontal approach. Furthermore, there was no CSF leakage in previous reports on the contralateral approach.^{13,14} In contrast, CSF leakage and meningitis are still substantial concerns in the transsphenoidal approach.9 Hypopituitarism was also a rare complication in our study. The pituitary stalk was identified in the early surgical phase because of tumor compressing the pituitary stalk posteromedially. Early detection of the pituitary stalk without blind dissection or detachment prevents hypopituitarism caused by pituitary stalk injury. Two postoperative cases of hypopituitarism in this series occurred in midline TSMs, in which the pituitary stalk was compressed far posteriorly and detected in the late surgical phase. In other transcranial and transsphenoidal approaches, the pituitary stalk is located in the back-most surgical corridor and identified in the late surgical phase with blind dissec-

ואטרר ט. בווטומומוס וסי		ונו מומרכו מו מאא										
	No. of	Visual	Improved After	Unchanged After	Worsened After	GTR	Complications	Recurrence	CSF	Hypopituitarism	No. of	Mean FU
Authors & Year	Patients	Assessment	Surgery (%)	Surgery (%)	Surgery (%)	(%)	(%)	(%)	Leakage	(%)	Deaths	(som)
Jang et al., 2012 ²	24	24	17 (71)	5 (21)	2 (8)	24 (100)	4 (17)	2 (8)	0	0	0	20
Engelhardt et al., 201814	20	20	14 (70)	3 (15)	3 (15)	18 (80)	5 (25)	1 (5)	0	0	0	66
Voznyak et al., 2021 ¹³	17	17	13 (76)	3 (18)	1 (6)	15 (88)	0	0	0	0	0	NA
Troude et al., 2021 ⁴⁵	36	NA	NA	NA	NA	30 (83)	NA	NA	0	NA	0	59
Present study	74	74	46 (62)	21 (29)	7 (9)	70 (96)	10 (14)	4 (5)	0	2 (3)	0	63

tion or detachment, causing accidental pituitary stalk injury. A specific drawback of the contralateral approach is the possibility of damaging the approach-side optic nerve. However, damage to the less-compromised optic nerve can occur even after other transcranial or transsphenoidal approaches.^{15–18} Furthermore, the tumor does not adhere to the approach-side optic nerve and can be separated only after internal debulking without manipulation of the optic nerve in most cases. Preoperative anxiety, postoperative fatigue, and memory difficulty in transcranial approaches and decreased olfactory function in transsphenoidal approaches are considerable issues that affect patient satisfaction.¹⁹

For patient selection, tumor laterality and visual symptoms are indicators to apply to the contralateral approach. In lateralized tumors, the approach-side optic nerve is expected to be free from tumor and the approach-side optic nerve does not interfere with the main working space. A lateralized tumor is considered an absolute indication for the contralateral subfrontal approach. In midline tumors, unilateral visual symptoms or asymmetrical bilateral visual symptoms suggest that the tumor does not adhere to the approach-side optic nerve and is expected to detach from the nerve by internal debulking and dissection without nerve manipulation. In our study, visual outcomes, complications, and tumor control were not significantly related to tumor laterality. However, 6 patients experienced deteriorated approach-side-only visual function with a favorable lesion-side visual outcome, and almost all tumors were located in the midline, except in 1 case. Considering asymmetrical visual impairment, the visual field defect in the approach-side optic nerve should be better than hemianopsia (< 50% visual field defect). There were 3 cases of tumor located in the midline with asymmetrical visual symptoms worse than hemianopsia in the approach-side optic nerve. One patient experienced worse visual function in the approach-side optic nerve, and 2 experienced surgical complications. Thus, a midline tumor is considered a relative indication for the contralateral subfrontal approach only when the less-compromised optic nerve has a visual field defect better than hemianopsia.

Compared to the transsphenoidal approach, the microsurgically available contralateral subfrontal approach is familiar to neurosurgeons and makes it easy to dissect the tumor from surrounding neurovascular structures in direct and wide surgical views. The contralateral subfrontal approach, like other transcranial approaches, also has the advantage of controlling lateralized tumor and accidental vascular injury.20 However, the contralateral subfrontal approach has some weak points, which include the possibility of manipulating the approach-side optic nerve. In our series, 5 patients with complete vision loss on the lesionside and intact vision on the approach-side were treated with the contralateral approach. Except for 1 patient with postoperative ICH, there were good surgical outcomes. Theoretically, it may seem that the normal optic nerve is at risk, but in practice such a risk can be avoided. Other approaches to the anterior skull base, such as cranioorbital and craniozygomatic approaches, could increase the angle of exposure and working space while reducing the need for brain retraction but still offer limited exposure of the

J Neurosurg Volume 138 • March 2023 607

Kim et al.

inferomedial side of the lesion-side optic nerve. Thus, the choice of surgical approach should be based on the characteristics of the tumor and the knowledge of the surgeon. The tumors included in our study had unilateral locations or a midline location causing unilateral visual symptoms or bilateral asymmetrical visual symptoms. Other tumors, such as midline tumors with bilateral symmetrical visual symptoms, were treated using other transcranial approaches, such as a bifrontal interhemispheric approach; however, those tumors were beyond the scope of this study. This retrospective study had certain limitations, such as a single institution's experience. A larger patient group with a longer follow-up duration and a similar patient group undergoing surgery via the transsphenoidal approach or other transcranial approaches are required for further studies. Although further prospective studies are necessary to verify the optimal surgical approach, the present study will help neurosurgeons treat TSMs properly.

Conclusions

The contralateral subfrontal approach provides an outstanding surgical field for TSM surgery with excellent visual outcomes and limited complications. Tumors presenting at a unilateral location or a midline location causing unilateral visual symptoms or bilateral asymmetrical visual symptoms are suitable for this approach. Based on an exact preoperative assessment to select appropriate patients and fine intraoperative techniques, the contralateral subfrontal approach may be a good choice for treating TSMs, as presented here.

Acknowledgments

This study was financially supported by Chonnam National University.

References

- Nimmannitya P, Goto T, Terakawa Y, et al. Characteristic of optic canal invasion in 31 consecutive cases with tuberculum sellae meningioma. *Neurosurg Rev.* 2016;39(4):691-697.
- Jang WY, Jung S, Jung TY, Moon KS, Kim IY. The contralateral subfrontal approach can simplify surgery and provide favorable visual outcome in tuberculum sellae meningiomas. *Neurosurg Rev.* 2012;35(4):601-608.
- 3. Esterman B. Functional scoring of the binocular field. *Oph-thalmology*. 1982;89(11):1226-1234.
- Magill ST, Morshed RA, Lucas CG, et al. Tuberculum sellae meningiomas: grading scale to assess surgical outcomes using the transcranial versus transsphenoidal approach. *Neurosurg Focus*. 2018;44(4):E9.
- Schick U, Hassler W. Surgical management of tuberculum sellae meningiomas: involvement of the optic canal and visual outcome. *J Neurol Neurosurg Psychiatry*. 2005;76(7): 977-983.
- Rogers L, Barani I, Chamberlain M, et al. Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. *J Neurosurg*. 2015;122(1):4-23.
- 7. Rhoton AL Jr. The sellar region. *Neurosurgery*. 2002;51(4) (suppl):S335-S374.
- Yamaki T, Tanabe S, Sohma T, Uede T, Shinya T, Hashi K. Feeding arteries of parasellar meningiomas—angiographic study of medial sphenoid ridge and tuberculum sellae meningiomas. *Neurol Med Chir (Tokyo)*. 1988;28(6):553-558.
- 9. Song SW, Kim YH, Kim JW, et al. Outcomes after trans-

608 J Neurosurg Volume 138 • March 2023

cranial and endoscopic endonasal approach for tuberculum meningiomas—a retrospective comparison. *World Neuro-surg.* 2018;109:e434-e445.

- Lee S, Hong SH, Cho YH, Kim JH, Kim CJ. Anatomical origin of tuberculum sellae meningioma: off-midline location and its clinical implications. *World Neurosurg*. 2016;89:552-561.
- Galal A, Faisal A, Al-Werdany M, El Shehaby A, Lotfy T, Moharram H. Determinants of postoperative visual recovery in suprasellar meningiomas. *Acta Neurochir (Wien)*. 2010; 152(1):69-77.
- Bassiouni H, Asgari S, Stolke D. Tuberculum sellae meningiomas: functional outcome in a consecutive series treated microsurgically. *Surg Neurol*. 2006;66(1):37-45.
- Voznyak O, Lytvynenko A, Maydannyk O, Ilyuk R, Zinkevych Y, Hryniv N. Tuberculum sellae meningioma surgery: visual outcomes and surgical aspects of contralateral approach. *Neurosurg Rev.* 2021;44(2):995-1001.
- Engelhardt J, Namaki H, Mollier O, et al. Contralateral transcranial approach to tuberculum sellae meningiomas: longterm visual outcomes and recurrence rates. *World Neurosurg*. 2018;116:e1066-e1074.
- Cai M, Hou B, Luo L, Zhang B, Guo Y. Trans-eyebrow supraorbital keyhole approach to tuberculum sellae meningiomas: a series of 30 cases with long-term visual outcomes and recurrence rates. *J Neurooncol*. 2019;142(3):545-555.
- Park CK, Jung HW, Yang SY, Seol HJ, Paek SH, Kim DG. Surgically treated tuberculum sellae and diaphragm sellae meningiomas: the importance of short-term visual outcome. *Neurosurgery*. 2006;59(2):238-243.
- Kitano M, Taneda M, Nakao Y. Postoperative improvement in visual function in patients with tuberculum sellae meningiomas: results of the extended transsphenoidal and transcranial approaches. *J Neurosurg*. 2007;107(2):337-346.
- Jallo GI, Benjamin V. Tuberculum sellae meningiomas: microsurgical anatomy and surgical technique. *Neurosurgery*. 2002;51(6):1432-1440.
- Khalafallah AM, Rakovec M, Burapachaisri K, et al. The Suprasellar Meningioma Patient-Reported Outcome Survey: a disease-specific patient-reported outcome measure for resection of suprasellar meningioma. *J Neurosurg*. Published online October 22, 2021. doi:10.3171/2021.6.JNS21517
- Giammattei L, Starnoni D, Cossu G, et al. Surgical management of tuberculum sellae meningiomas: myths, facts, and controversies. *Acta Neurochir (Wien)*. 2020;162(3):631-640.
- 21. Wang CW, Li YY, Zhu SG, et al. Surgical management and evaluation of prognostic factors influencing postoperative visual outcome of suprasellar meningiomas. *World Neurosurg*. 2011;75(2):294-302.
- Chokyu I, Goto T, Ishibashi K, Nagata T, Ohata K. Bilateral subfrontal approach for tuberculum sellae meningiomas in long-term postoperative visual outcome. *J Neurosurg.* 2011; 115(4):802-810.
- Li-Hua C, Ling C, Li-Xu L. Microsurgical management of tuberculum sellae meningiomas by the frontolateral approach: surgical technique and visual outcome. *Clin Neurol Neurosurg*. 2011;113(1):39-47.
- Curey S, Derrey S, Hannequin P, et al. Validation of the superior interhemispheric approach for tuberculum sellae meningioma: clinical article. *J Neurosurg.* 2012;117(6):1013-1021.
- Palani A, Panigrahi MK, Purohit AK. Tuberculum sellae meningiomas: a series of 41 cases; surgical and ophthalmological outcomes with proposal of a new prognostic scoring system. J Neurosci Rural Pract. 2012;3(3):286-293.
- Romani R, Laakso A, Kangasniemi M, Niemelä M, Hernesniemi J. Lateral supraorbital approach applied to tuberculum sellae meningiomas: experience with 52 consecutive patients. *Neurosurgery*. 2012;70(6):1504-1519.

- Mortini P, Barzaghi LR, Serra C, Orlandi V, Bianchi S, Losa M. Visual outcome after fronto-temporo-orbito-zygomatic approach combined with early extradural and intradural optic nerve decompression in tuberculum and diaphragma sellae meningiomas. *Clin Neurol Neurosurg*, 2012;114(6):597-606.
- Margalit N, Shahar T, Barkay G, et al. Tuberculum sellae meningiomas: surgical technique, visual outcome, and prognostic factors in 51 cases. *J Neurol Surg B Skull Base*. 2013; 74(4):247-258.
- 29. Seol HJ, Park HY, Nam DH, et al. Clinical outcomes of tuberculum sellae meningiomas focusing on reversibility of postoperative visual function. *Acta Neurochir (Wien)*. 2013; 155(1):25-31.
- Mariniello G, de Divitiis O, Bonavolontà G, Maiuri F. Surgical unroofing of the optic canal and visual outcome in basal meningiomas. *Acta Neurochir (Wien)*. 2013;155(1):77-84.
- Liu HC, Qiu E, Zhang JL, et al. Surgical indications of exploring optic canal and visual prognostic factors in neurosurgical treatment of tuberculum sellae meningiomas. *Chin Med J (Engl).* 2015;128(17):2307-2311.
- Zhou H, Wu Z, Wang L, Zhang J. Microsurgical treatment of tuberculum sellae meningiomas with visual impairments: a Chinese experience of 56 cases. *Turk Neurosurg.* 2016;26(1): 48-53.
- Karsy M, Raheja A, Eli I, Guan J, Couldwell WT. Clinical outcomes with transcranial resection of the tuberculum sellae meningioma. *World Neurosurg*. 2017;108:748-755.
- Kong DS, Hong CK, Hong SD, et al. Selection of endoscopic or transcranial surgery for tuberculum sellae meningiomas according to specific anatomical features: a retrospective multicenter analysis (KOSEN-002). *J Neurosurg*. 2018; 130(3):838-847.
- 35. Xu M, Xu J, Huang X, Chen D, Chen M, Zhong P. Small extended bifrontal approach for midline anterior skull base meningiomas: our experience with 54 consecutive patients. *World Neurosurg*. 2019;125:e35-e43.
- Van Gompel JJ, Frank G, Pasquini E, Zoli M, Hoover J, Lanzino G. Expanded endonasal endoscopic resection of anterior fossa meningiomas: report of 13 cases and meta-analysis of the literature. *Neurosurg Focus*. 2011;30(5):E15.
- Ogawa Y, Tominaga T. Extended transsphenoidal approach for tuberculum sellae meningioma—what are the optimum and critical indications? *Acta Neurochir (Wien)*. 2012;154(4): 621-626.
- Khan OH, Krischek B, Holliman D, et al. Pure endoscopic expanded endonasal approach for olfactory groove and tuberculum sellae meningiomas. *J Clin Neurosci*. 2014;21(6): 927-933.
- Ceylan S, Anik I, Koc K, Cabuk B. Extended endoscopic transsphenoidal approach infrachiasmatic corridor. *Neuro*surg Rev. 2015;38(1):137-147.
- 40. Hayashi Y, Kita D, Fukui I, et al. Preoperative evaluation of the interface between tuberculum sellae meningioma and the optic nerves on fast imaging with steady-state acquisition for extended endoscopic endonasal transsphenoidal surgery. *World Neurosurg.* 2017;103:153-160.

- 41. Bander ED, Singh H, Ogilvie CB, et al. Endoscopic endonasal versus transcranial approach to tuberculum sellae and planum sphenoidale meningiomas in a similar cohort of patients. *J Neurosurg*. 2018;128(1):40-48.
- Elshazly K, Kshettry VR, Farrell CJ, Nyquist G, Rosen M, Evans JJ. Clinical outcome after endoscopic endonasal resection of tuberculum sella meningiomas. *Oper Neurosurg* (*Hagerstown*). 2018;14(5):494-502.
- 43. Youngerman BE, Banu MA, Gerges MM, et al. Endoscopic endonasal approach for suprasellar meningiomas: introduction of a new scoring system to predict extent of resection and assist in case selection with long-term outcome data. *J Neurosurg*. 2021;135(1):113-125.
- 44. Yu P, Xu T, Wu X, Liu Z, Wang Y, Wang Y. The expanded endoscopic endonasal approach for treatment of tuberculum sellae meningiomas in a series of 40 consecutive cases. *Sci Rep.* 2021;11(1):4993.
- 45. Troude L, Boucekine M, Baucher G, et al. Ipsilateral vs controlateral approach in tuberculum sellae meningiomas surgery: a retrospective comparative study. *Neurosurg Rev.* 2021;44(6):3581-3591.

Disclosures

The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.

Author Contributions

Conception and design: S Jung, Jang. Acquisition of data: YJ Kim, Jang. Analysis and interpretation of data: YJ Kim. Drafting the article: YJ Kim. Critically revising the article: Moon, IY Kim. Reviewed submitted version of manuscript: Moon, TY Jung. Statistical analysis: YJ Kim. Administrative/technical/material support: TY Jung, IY Kim.

Supplemental Information

Online-Only Content

Supplemental material is available with the online version of the article.

Supplemental Fig. 1. https://thejns.org/doi/suppl/10.3171/2022.5.JNS212899.

Correspondence

Shin Jung: Chonnam National University Research Institute of Medical Science, Chonnam National University Hwasun Hospital and Medical School, Hwasun, Jeollanam-do, South Korea. sjung@ chonnam.ac.kr.